Skip to main content
NewslettersWatchlist

Kronos Bio Inc(KRON-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.9820
Day High1.0400
Open:1.0000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
5 Microcap Stocks With 65% or More Upside Potential
Newswire.ca
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
Globe Newswire
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress
Globe Newswire
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress
Globe Newswire
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR
Globe Newswire
Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022
Globe Newswire
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference
Globe Newswire
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results
Globe Newswire
Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
Globe Newswire
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
Globe Newswire
Kronos Bio Announces Participation in Upcoming Investor Conferences
Globe Newswire
Kronos Bio Appoints Roshawn Blunt to Board of Directors
Globe Newswire
Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results
Globe Newswire
Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform
Globe Newswire
Kronos Bio Announces Participation in the BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology
Globe NewsWire
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021
Globe NewsWire
Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations
Globe NewsWire
Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
Globe NewsWire
Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results
Globe NewsWire
Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)
Globe NewsWire
Kronos Bio Announces Participation in Upcoming Investor Conferences
Globe NewsWire
Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today
Globe NewsWire
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day
Globe NewsWire
Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference
Globe NewsWire
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021
Globe NewsWire
Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.
Globe NewsWire
Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors
Globe NewsWire
Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
Globe NewsWire
Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
Globe NewsWire
Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)
Globe NewsWire
Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
Globe NewsWire
Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference

Profile

Kronos Bio Inc. is a clinical-stage biopharmaceutical company. It engages in discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Kronos Bio Inc. is headquartered in San Mateo, Calif.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.